Bortezomib Evidence Guide
Bortezomib (Velcade) is FDA-approved for multiple myeloma and mantle cell lymphoma, with Phase 3 data across numerous trials establishing it as the foundational proteasome inhibitor in oncology. It was the first proteasome inhibitor approved and remains a backbone of myeloma treatment protocols worldwide. An extensively validated cancer therapeutic.
Our Take
Bortezomib (Velcade) is FDA-approved for multiple myeloma and mantle cell lymphoma, with Phase 3 data across numerous trials establishing it as the foundational proteasome inhibitor in oncology. It was the first proteasome inhibitor approved and remains a backbone of myeloma treatment protocols worldwide. An extensively validated cancer therapeutic.
- Evidence context
- Multiple myeloma (newly diagnosed and relapsed), mantle cell lymphoma, proteasome biology research
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 1.3mg/m² subcutaneous or IV twice weekly for 2 of every 3 weeks (standard cycle)
Benefits and Evidence
- Multiple Myeloma Treatment: Level A, includes human evidence - Landmark VISTA trial demonstrated superior overall survival when added to melphalan-prednisone in newly diagnosed myeloma patients ineligible for transplant.
- Mantle Cell Lymphoma: Level A, includes human evidence - Approved for relapsed mantle cell lymphoma with response rates of approximately 30-50% as monotherapy in the relapsed setting.
- Peripheral Neuropathy: Level A, includes human evidence - Dose-limiting peripheral neuropathy affects 30-40% of patients. Subcutaneous administration reduces incidence compared to intravenous.
- Bone Health Improvement: Level B, includes human evidence - Proteasome inhibition promotes osteoblast differentiation, and bortezomib has shown beneficial effects on bone metabolism in myeloma patients.
Side Effects and Warnings
- Peripheral neuropathy (sensory and motor)
- Thrombocytopenia (cyclical, platelet nadir at day 11)
- Nausea and diarrhea
- Fatigue
- Herpes zoster reactivation
- Peripheral neuropathy - dose modification required with new onset or worsening
- Thrombocytopenia - monitor platelet counts regularly
- Herpes zoster prophylaxis recommended (acyclovir)
Research Dosage References
- <strong>Subcutaneous injection</strong> - 1.3 mg/m2 - Days 1, 4, 8, 11 of 21-day cycle - Subcutaneous preferred over IV due to reduced peripheral neuropathy risk. Rotate injection sites.
- <strong>Intravenous bolus</strong> - 1.3 mg/m2 - Days 1, 4, 8, 11 of 21-day cycle - Original approved route. 3-5 second bolus injection. Higher neuropathy risk than subcutaneous.
- <strong>Subcutaneous injection</strong> - 1.3 mg/m2 - Weekly (days 1, 8, 15, 22 of 35-day cycle) - Weekly schedule used for reduced toxicity in maintenance or elderly patients.
Mechanism of Action
Bortezomib disrupts protein homeostasis through reversible proteasome inhibition: 1. 26S proteasome inhibition: Reversibly binds to the beta-5 subunit chymotrypsin-like active site, blocking protein degradation. 2. NF-kB pathway suppression: Prevents proteasomal degradation of IkB-alpha, inhibiting NF-kB-mediated survival signaling in myeloma cells. 3. Unfolded protein response: Triggers ER stress and unfolded protein response in myeloma cells, which are highly dependent on protein quality control. 4. Microenvironment disruption: Inhibits angiogenesis and myeloma cell adhesion to bone marrow stromal cells, reducing pro-survival paracrine signaling.
Legal Status
FDA-approved for multiple myeloma (2003) and mantle cell lymphoma (2006). Available by prescription only. Marketed as Velcade by Takeda. Generic versions available.
Primary Sources
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma (VISTA). N Engl J Med, 2008.
- Subcutaneous versus intravenous bortezomib in multiple myeloma. Lancet Oncol, 2011.
- Bortezomib in relapsed mantle cell lymphoma. J Clin Oncol, 2006.
Quick Answers
Where is the strongest evidence for Bortezomib?
Bortezomib (Velcade) is FDA-approved for multiple myeloma and mantle cell lymphoma, with Phase 3 data across numerous trials establishing it as the foundational proteasome inhibitor in oncology. It was the first proteasome inhibitor approved and remains a backbone of myeloma treatment protocols worldwide. An extensively validated cancer therapeutic. Evidence context: Multiple myeloma (newly diagnosed and relapsed), mantle cell lymphoma, proteasome biology research.
What are the main side effects of Bortezomib?
Bortezomib side effects and warning signals include Peripheral neuropathy (sensory and motor), Thrombocytopenia (cyclical, platelet nadir at day 11), Nausea and diarrhea, Fatigue, and Herpes zoster reactivation.
What evidence level is Bortezomib?
Bortezomib is rated Level A; the listed research status is FDA Approved.